יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Tharimmune, Inc. (THAR)

The development of Tharimmune, Inc. (THAR) relies on antibody trial results for oncology and dermatitis therapies with moderate R&D expenditures. Tharimmune, Inc. (THAR) is creating unique targeted drugs protected by patents and a debt-free balance sheet. The company maintains structural flexibility through production outsourcing. This price action on GURU.Markets illustrates an EV/EBITDA of 0.00, confirming the current market valuation of the business.

For Tharimmune, Inc. (THAR), which faces a systematic capital outflow for antibody development, the company's EV/EBITDA ratio over a time series serves as an indicator of the total business value relative to its operational efficiency. This metric combines market capitalization and net debt, allowing an investor to assess the real value of assets compared to the generated earnings before interest, taxes, depreciation, and amortization.